Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE Platform at 2026 ASGCT Annual Meeting
CUAI - Copper Intelligence Extensive Drilling Program Continues to Validate Significant Copper System at Butembo, Eastern DRC
Syntholene Completes Phase One of Effects Testing at Iceland Demonstration Facility, Advances to High-Power Operations
